Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?

To: Mike who wrote (1802)	8/28/2003 8:28:22 PM
From: SemiBull	Respond to of 3044

Newsmakers in the Biotech Industry Conference to Webcast Millennium Pharmaceuticals, Inc. Presentation Thursday August 28, 4:01 pm ET CAMBRIDGE, Mass., Aug. 28 /PRNewswire-FirstCall/-- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM - News) announced today that its presentation at the Newsmakers in the Biotech Industry Conference will be webcast live and may be accessed by visiting the Investors section of the Company's website, www.millennium.com. Millennium senior management will provide an overview of the Company and progress against 2003 goals. The presentation will be delivered at 2:20 p.m. EDT on Thursday, September 4, 2003 from The Millennium Broadway Hotel in New York City. The presentation will be archived for 30 days. About Millennium Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., co-promotes INTEGRILIN® (eptifibatide) Injection, a market-leading cardiovascular product, markets VELCADE(TM) (bortezomib) for Injection, a novel cancer product, and has a robust clinical development pipeline of product candidates. The Company's research, development and commercialization activities are focused in three disease areas: cardiovascular, oncology and inflammation. By applying its knowledge of the human genome, its understanding of disease mechanisms, and its industrialized technology platform, Millennium is seeking to develop breakthrough personalized medicine products. Editors' Note: This press release is also available under the Media section of the Company's website at: www.millennium.com. Contact: Cynthia Clayton, Investor Relations Millennium Pharmaceuticals, Inc. (617) 551-8607

To: Mike who wrote (1802)	9/6/2003 10:35:18 AM
From: Mike	Read Replies (1) \| Respond to of 3044

Huh, I get nailed for bringing up something that directly affects MLNM. This below. Just wait for the next two qtrs results this puppy is going to lose so much money. Mike Prediction. For each dollar that MDCO increases sales of Angiomax MLNM will lose a $1.30 in Integrilin sales. I am not hyping MDCO but warning you the investors in MLNM. MLNM is not losing people left and right due to such a great pipeline. They are losing people and laying off people because things look bleak. MLNM is a company with no outlook or plan to make a profit. They having shiny things behind the curtain that sound and look great. The only problem is these products are not being managed. This is like a freak show at your local State Fair. You have a bunch of stuffy people on this board that hate to hear or look at the truth. "Mommy they aren't playing fair. Their not supposed to be able to tell the truth." So stick your head in the sand and listen to the stuffies that don't want the truth to be told. This stock is going to single digits. Mike